Fig. 3From: Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicityComplete reponse observed in a 79 year-old male with stage IV melanoma treated with IMM-101 followed by pembrolizumab (lung disease)Back to article page